XORTX Therapeutics Inc. (XRTX.V)
CAD 1.2
(-10.45%)
CAD 1.2
(-10.45%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -6.46 Million CAD | 39.16% |
| 2022 | -9.41 Million CAD | -157.95% |
| 2021 | -1.62 Million CAD | -222.0% |
| 2020 | -1.25 Million CAD | -134.42% |
| 2019 | -572.46 Thousand CAD | 52.01% |
| 2018 | -1.06 Million CAD | -151.38% |
| 2017 | -427.1 Thousand CAD | -16.27% |
| 2016 | -389.31 Thousand CAD | 0.0% |
| 2014 | -36.92 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 905.43 Thousand USD | 7.18% |
| 2024 Q2 | -3.08 Million USD | -78.03% |
| 2023 Q2 | -1.72 Million USD | 6.64% |
| 2023 FY | - CAD | 25.02% |
| 2023 Q3 | -1.37 Million USD | 20.45% |
| 2023 Q4 | -4.59 Million USD | -234.44% |
| 2023 Q1 | -1.84 Million USD | -18.09% |
| 2022 Q2 | -5.16 Million CAD | -33.99% |
| 2022 Q1 | -3.85 Million CAD | -22.58% |
| 2022 Q4 | -1.56 Million CAD | 59.36% |
| 2022 Q3 | -3.85 Million CAD | 25.35% |
| 2022 FY | - CAD | -157.95% |
| 2021 FY | - CAD | -222.0% |
| 2021 Q4 | -3.14 Million CAD | -684.81% |
| 2021 Q2 | -861.07 Thousand CAD | -1.07% |
| 2021 Q1 | -851.94 Thousand CAD | -127.06% |
| 2021 Q3 | -400.34 Thousand CAD | 53.51% |
| 2020 Q4 | -375.2 Thousand CAD | 0.39% |
| 2020 Q2 | -365.79 Thousand CAD | -125.28% |
| 2020 Q1 | -162.37 Thousand CAD | -1.57% |
| 2020 FY | - CAD | -134.42% |
| 2020 Q3 | -376.68 Thousand CAD | -2.98% |
| 2019 Q1 | -122.73 Thousand CAD | -104.95% |
| 2019 FY | - CAD | 52.01% |
| 2019 Q2 | -135.28 Thousand CAD | -10.23% |
| 2019 Q4 | -159.87 Thousand CAD | -24.74% |
| 2019 Q3 | -128.16 Thousand CAD | 5.26% |
| 2018 Q1 | -3.05 Million CAD | -1154.82% |
| 2018 Q4 | 2.47 Million CAD | 956.01% |
| 2018 Q2 | -272.68 Thousand CAD | 91.07% |
| 2018 Q3 | -289.49 Thousand CAD | -6.17% |
| 2018 FY | - CAD | -151.38% |
| 2017 Q1 | -63 Thousand CAD | -9.63% |
| 2017 FY | - CAD | -16.27% |
| 2017 Q4 | -243.36 Thousand CAD | -189.17% |
| 2017 Q3 | -84.16 Thousand CAD | -77.26% |
| 2017 Q2 | -47.48 Thousand CAD | 24.65% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q4 | -57.47 Thousand CAD | -10.37% |
| 2016 Q3 | -52.07 Thousand CAD | -17.8% |
| 2016 Q2 | -44.2 Thousand CAD | -425.13% |
| 2016 Q1 | 13.59 Thousand CAD | 112.47% |
| 2015 Q1 | -17.39 Thousand CAD | -171.9% |
| 2015 Q2 | -62.62 Thousand CAD | -259.93% |
| 2015 Q4 | -109.05 Thousand CAD | -134.24% |
| 2015 Q3 | -46.55 Thousand CAD | 25.66% |
| 2014 Q3 | -6678.00 CAD | -3.6% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q2 | -6446.00 CAD | 0.0% |
| 2014 Q4 | -6399.00 CAD | 4.18% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Arch Biopartners Inc. | -430.71 Thousand CAD | -1401.822% |
| Covalon Technologies Ltd. | -3.49 Million CAD | -85.261% |
| Hemostemix Inc. | -1.94 Million CAD | -232.446% |
| Universal Ibogaine Inc. | -4.6 Million CAD | -40.397% |
| Kane Biotech Inc. | -3.23 Million CAD | -99.994% |
| MedMira Inc. | -1.57 Million CAD | -310.123% |
| Marvel Biosciences Corp. | -2.25 Million CAD | -187.237% |
| NervGen Pharma Corp. | -17.72 Million CAD | 63.499% |